Concepedia

Author

Gabriel Tremblay

Novartis (United States)ORCID

Also Known As

G TREMBLAY, G Tremblay, G. Tremblay, Gabriel Tremblay, Tremblay G

133

Publications

633

Citations

13

H-Index

17

Concepts

All Affiliations

Novartis (United States)Cytel (United States)University of GlasgowEisai (United States)Otto-von-Guericke University Magdeburg
GT

About

Gabriel Tremblay is an author at Novartis (United States) specializing in medicine, hematology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

54

2

Health Sciences

1

1

13

3

Cellular Physiology

1

1

19

4

Gastroenterology

1

1

19

5

Health Policy

1

1

13

Gabriel Tremblay

×

20

Publications

342

Citations

12

H-Index

YearCitations

Economic Evaluation of Cost and Time Required for a Platform Trial vs Conventional Trials

Jay Park, Behnam Sharif, Ofir Harari,

JAMA Network Open

2022

44

Systematic review of health state utility values for acute myeloid leukemia

Anna Forsythe, Patricia Brandt, Mike Dolph,

ClinicoEconomics and Outcomes Research

2018

31

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer

Gabriel Tremblay, David Chandiwana, Mike Dolph,

Cancer Management and Research

2018

25

Effectiveness of crizotinib versus entrectinib in <i>ROS1</i> -positive non-small-cell lung cancer using clinical and real-world data

Gabriel Tremblay, M Groff, Laura Iadeluca,

Future Oncology

2022

21

A Criterion-based Approach for the Systematic and Transparent Extrapolation of Clinical Trial Survival Data

Gabriel Tremblay, Patrick A. Haines, Andrew Briggs

Journal of health economics and outcomes research

2015

21

Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer

Hayley de Freitas, Cicely Kerr, Beth Fordham,

Patient Preference and Adherence

2015

19

Argentaffine cells in chronic cholecystitis.

L Delaquerriere, Gabriel Tremblay, Riopelle Jl

PubMed

1962

19

Potassium-Competitive Acid Blocker and Proton Pump Inhibitor–Based Regimens for First-Line Helicobacter pylori Eradication: A Network Meta-Analysis

Peter Malfertheiner, Steven F. Moss, Patrick Daniele,

Gastro Hep Advances

2022

17

Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom

Gabriel Tremblay, Mike Dolph, Sachin Patel,

Cost Effectiveness and Resource Allocation

2018

15

THU0329 SAFETY, TARGET ENGAGEMENT, AND INITIAL EFFICACY OF AVID200, A FIRST-IN-CLASS POTENT AND ISOFORM-SELECTIVE INHIBITOR OF TGF-BETA 1 AND 3, IN PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC): A PHASE 1 DOSE ESCALATION STUDY

Robert Lafyatis, Robert Spiera, Robin Domsic,

Annals of the Rheumatic Diseases

2020

15

Page 1